1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Insulet Corporation

Insulet Corporation , headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.
Shacey Petrovic

100 Nagog Park
Acton, Massachusetts 01720-3440
Phone: 19786007000


Insider Sale at Insulet Corp (PODD) by SVP & Chief Technology Officer Mark Field
Jun 17, 2024 23:01pm

Insider Sale at Insulet Corp (PODD) by SVP & Chief Technology Officer Mark Field

Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023
Jun 11, 2024 20:27pm

Insulet''s CEO believes that GLP-1 drugs are increasing the adoption of insulin, suggesting a positive impact on the iCGM industry. Read more on PODD stock here.

Source:Seeking Alpha
7 Stocks That Could Safely 10X by 2030
Jun 06, 2024 10:19am

There is no such thing as safe gains in the market, at least in the near term. However, many stocks are very solid and won’t disappoint you in the long run. Wall Street often pays a premium for such solid companies, but if you buy companies with huge growth runways and margins that are expanding fast, the stars could align for you. Even if these picks don’t turn out to be 10x stocks by 2030, I have solid conviction they will at least deliver market-beating returns if they continue executing as they have. Buying up solidly profitable companies with big moats is a time-tested and proven way to realize outsized gains. Here are seven possible 10x stocks worth looking into. Cloudflare (NET) Source: IgorGolovniov / Shutterstock.com Cloudflare (NYSE: NET ) provides vital internet security and performance services to a huge portion of the web. With a 97.81% market share in cloud security and a client base spanning most small and medium-sized websites, Cloudflare has become an essential player in our increasingly digital world.

Insulet, Tandem new buys from Redburn Atlantic in diabetes technology space
May 30, 2024 17:39pm

No summary available.

Source:Seeking Alpha
Redburn-Atlantic initiates Buy on Insulet stock, cites growth prospects
May 30, 2024 08:54am


Insulet to Present at the Jefferies Global Healthcare Conference
May 28, 2024 10:00am

Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced that management will present at the Jefferies Global Healthcare Conference in New York City on Thursday, June 6, 2024 at 9:00 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit investors.insulet.com/events. Jetzt den vollständigen Artikel lesen

Will Insulet''s Monopoly Crumble? Appellate Court Ruling Signals Shift in Automated Insulin Delivery Systems Market
May 14, 2024 18:44pm

On Tuesday, Blue Orca Capital released a report on Insulet Corporation (NASDAQ: PODD ), saying it is short on the insulin delivery patch pump manufacturer. The report added that Blue Orca is long on its upstart Korean competitor EOFlow Co Ltd as last week the Court of Appeals for the Federal Circuit killed a preliminary injunction that protected Insulet’s key monopoly against competition from EOFlow. The report adds that the injunction is undisclosed to investors. The report notes, “In our opinion, it is highly misleading for Insulet to conceal from investors that the appellate court killed the very injunction which protected its competitive moat and was so material to its stock that, when the injunction was granted, its market capitalization gained $1.8 billion. This injunction is now dead. Competition is here.” Insulet … Full story available on Benzinga.com

Blue Orca goes short Insulet on undisclosed preliminary injunction defeat
May 14, 2024 18:11pm


Insulet Q1 Earnings Top, 2024 Revenue View Raised
May 13, 2024 19:33pm

Insulet Corporation (NASDAQ: PODD ) reported GAAP earnings per share of 73 cents for first-quarter 2024, which significantly improved from the year-ago period''s EPS of 34 cents. The figure also exceeded the Zacks Consensus Estimate by 87.2%. First-quarter 2023 adjusted earnings per share were 23 cents. Revenues Revenues in the first quarter totaled $441.7 million, beating the Zacks Consensus Estimate by 4.3%. The top line jumped 23.3% year over year (up 22.8% at the constant exchange rate or CER). CER growth exceeded the company''s guidance range of 17% to 20% projected growth from first-quarter 2023. Q1 in Detail Insulet''s Total Omnipod revenues of $433 million reflected an increase of 21.1% year over year (up 20.5% at CER). International Omnipod revenues of $115.3 million rose 16.9% (up 14.8% at CER). U.S. Omnipod revenues grew 22.7% year over year to $317.7 million. The Drug Delivery business revenues totaled $8.7 million compared with $0.5 million in the year-ago period. Insulet Corporation Price, Consensus and EPS Surprise Insulet Corporation price-consensus-eps-surprise-chart | Insulet Corporation Quote Margins Gross profit in the reported quarter was $306.8 million, up 27.6% from the prior-year quarter''s levels.

What the Options Market Tells Us About Insulet
May 13, 2024 18:30pm

Deep-pocketed investors have adopted a bullish approach towards Insulet (NASDAQ: PODD ), and it''s something market players shouldn''t ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in PODD usually suggests something big is about to happen. We gleaned this information from our observations today when Benzinga''s options scanner highlighted 20 extraordinary options activities for Insulet. This level of activity is out of the ordinary. The general mood among these heavyweight investors is divided, with 80% leaning bullish and 5% bearish. Among these notable options, 17 are puts, totaling $724,171, and 3 are calls, amounting to $144,000. Projected Price Targets Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $165.0 to $180.0 for Insulet over the last 3 months. Insights into Volume & Open Interest Assessing the volume and open interest …